Our deep expertize of the Polish healthcare market is displayed in our research. It allows it so objectively, competently and with credibility describe the reality in many fields of healthcare.
- Oncology patients’ access to drug therapies in Poland in view of current medical knowledge
A report prepared by PEX PharmaSequence for the Alivia Oncology Foundation financed with a grant from the Council of Employers of Poland
- RSA in Drug Reimbursement System in Poland and Abroad
Executive summary of a report prepared by Sequence, HTA Consulting and Ryś & Associates Law Firm. The publication deals with the use of risk sharing agreements in introduction of new drugs to the reimbursement system.
- Patient's price acceptance
Excerpt from a report on growth opportunities that PEX PharmaSequence delivered for a major international drug manufacturer